Similar articles

• Rethinking risk-benefit assessment for phase I cancer trials.

  Joffe S, Miller FG. Joffe S, et al. J Clin Oncol. 2006 Jul 1;24(19):2987-90. doi: 10.1200/JCO.2005.04.9296. J Clin Oncol. 2006. PMID: 16809725 No abstract available.
• Dynamic and modern: bringing the ethics of phase I trials up to date.

  Camidge DR, Eckhardt SG, Gore L. Camidge DR, et al. J Clin Oncol. 2006 Nov 10;24(32):5178-9; author reply 5179-80. doi: 10.1200/JCO.2006.09.1207. J Clin Oncol. 2006. PMID: 17093287 No abstract available.
• Phase I research and the meaning of direct benefit.

  Ross L. Ross L. J Pediatr. 2006 Jul;149(1 Suppl):S20-4. doi: 10.1016/j.jpeds.2006.04.046. J Pediatr. 2006. PMID: 16829237
• [How to prevent hazards and to reduce risk in clinical trials?].

  Czarkowski M. Czarkowski M. Pol Merkur Lekarski. 2008 Dec;25(150):534-8. Pol Merkur Lekarski. 2008. PMID: 19205390 Review. Polish.
• Controversies in multi-institutional phase I clinical trials.

  Dowlati A. Dowlati A. Clin Adv Hematol Oncol. 2009 Aug;7(8):518-20. Clin Adv Hematol Oncol. 2009. PMID: 19927978 Review. No abstract available.